Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Agilent Technologies Signals Steady Growth Amid Headwinds

📈 Agilent Technologies reported Q1 revenue of $1.8 billion, marking 4.4% core year-over-year growth.

💰 Non-GAAP operating margin stood at 24.6%, in line with analyst expectations, while EPS rose 4% to $1.36.

💱 Currency effects provided a 2.6% tailwind to reported results as foreign exchange rates worked in the company's favor.

🛒 The company generated $268 million in operating cash flow and returned $152 million to shareholders via buybacks.

🤖 The Ignite operating system doubled pricing realization and drove nearly 200 basis points of pricing power last quarter.

🧬 Pharma revenue surged 7% driven by a 50% increase in GLP-1 drug sales as that class of medication scales globally.

🏭 Advanced materials growth exceeded 20%, helping the chemicals and advanced materials segment rise 9%.

⚠️ A winter storm in Memphis delayed approximately $10 million of revenue, limiting Americas growth to just 1% in Q1.

📉 Academia and government spending declined 8% as U.S. customers prioritized operating budgets over new capital purchases.

🍎 Food testing revenue fell 4%, though performance appeared better when excluding China sales from the calculation.

🔬 The specialty CDMO business grew at a low double-digit rate with successful integration of the BIOVECTRA acquisition.

⚠️ Tariff costs reduced gross margin by about 100 basis points, though management views them as manageable headwinds.

🌍 Europe saw a temporary pause in purchasing as customers assessed tariff developments before returning to 4% growth.

🇨🇳 China delivered 6% revenue growth helped by pre-Lunar New Year spending despite uncertain large-scale stimulus effects.

🚀 Management kept the full-year core revenue growth outlook at 4%–6% with an updated FY26 non-GAAP EPS range of $5.90–$6.04.

Bullish Signals
  • Agilent Technologies posted Q1 revenue of $1.8 billion, translating into 4.4% core growth year over year and 7.0% reported growth.
  • Non-GAAP operating margin remained strong at 24.6%, in line with expectations, while EPS rose about 4% to $1.36.
  • Currency acted as a meaningful tailwind, adding 2.6% to reported results and supporting the company's earnings outlook.
  • Management increased the full-year non-GAAP EPS range guidance for FY26 to $5.90–$6.04, reflecting FX upside.
  • The company generated $268 million in operating cash flow while returning capital through $152 million in buybacks and $72 million in dividends.
  • Agilent's Ignite operating system doubled pricing realization versus prior baselines and drove nearly 200 basis points of pricing last quarter.
  • New products fueled significant share gains, with the Infinity III HPLC platform driving high-single-digit LC growth and Pro iQ single-quad LC/MS systems expanding more than 40%.
  • Pharma revenue grew 7%, driven by a surge of roughly 50% in GLP-1-related revenue as that class of drugs scales globally.
  • The chemicals and advanced materials segment rose 9%, aided by over 20% growth in advanced materials, while Altura columns helped push biocolumn growth above 30%.
  • Agilent's specialty CDMO business grew at a low double-digit rate in Q1, reinforcing its strategic role as a long-term growth driver with mid-teens expected this fiscal year.
  • The company secured a $9 million TSA contract for its Raman Insight BRT system in Q1, signaling strong competitive positioning.
Risk Factors
  • Academia and government spending declined 8% in Q1 as U.S. academic customers prioritized operating budgets over new capital purchases, with expectations for low single-digit declines for the full year tempering overall growth.
  • Food testing revenue declined 4%, and environmental and forensics sales were essentially flat, indicating softness in these specific segments.
  • A late-January winter storm hit Agilent's Americas logistics hub in Memphis, delaying roughly $10 million of revenue and limiting Americas growth to just 1% in Q1.
  • Tariff costs dragged Q1 gross margin down to 53.7%, about 100 basis points below last year, and shaved around 50 basis points off operating margin.
  • Europe saw temporary pauses in purchasing as customers assessed tariff developments, demonstrating how policy noise can influence buying behavior in that region.
  • Within Life Sciences & Diagnostics, LDG grew only 3% but lagged internal expectations due to weaker demand in certain cell analysis and genomics niches.
  • Specialty CDMO margins were uneven due to batch cadence, which can swing profitability in any single quarter, introducing margin volatility to the segment.
  • China growth was helped by modest pre-Lunar New Year spending and small stimulus effects, but management stressed that larger stimulus is still uncertain and not assumed in guidance.
  • Ongoing tariff policy changes remain a key external risk, especially given recent rulings that may reshape cost structures with the situation remaining fluid.
Full Analysis
Agilent Technologies (A) reported its Q1 2025 results, delivering revenue of $1.8 billion with core growth of 4.4% year over year and reported growth of 7.0%, supported by a 2.6% favorable foreign currency headwind. The company maintained its full-year core revenue growth guidance range of 4% to 6% while adjusting the fiscal year 2025 non-GAAP EPS outlook to $5.90–$6.04, reflecting the current FX advantage. Executive management highlighted that the Ignite operating system continues to drive efficiency and pricing power, doubling pricing realization versus prior baselines and contributing nearly 200 basis points to margins in Q1, while also aiding procurement savings and tariff mitigation efforts. Operating cash flow reached $268 million for the quarter, with significant capital returns made through $152 million in share buybacks and $72 million in dividends paid to shareholders. Revenue growth was uneven across end markets and geographies, with pharma emerging as a standout segment that grew 7%, largely driven by approximately 50% surge in revenue related to GLP-1 drugs. The chemicals and advanced materials segment increased by 9%, aided by over 20% growth in advanced materials, while diagnostics and clinical revenue climbed 7%. However, academia and government spending declined 8% as U.S. customers prioritized operating budgets, with the company now expecting a low single-digit decline for the full year. China delivered 6% growth due to pre-Lunar New Year activity and modest stimulus effects, though management noted that larger stimulus remains uncertain. Additionally, a winter storm in January impacted Agilent's Memphis logistics hub, delaying roughly $10 million of revenue and limiting Americas growth to just 1% for the quarter. Despite these challenges, Agilion’s specialty CDMO business grew at a low double-digit rate, reinforcing its long-term strategic importance, though margins experienced volatility due to batch timing which management expects is inherent to the model. Europe saw temporary purchasing pauses as customers assessed tariff developments, and food testing revenue declined 4%, excluding China, while environmental and forensics sales remained flat. The company successfully integrated BIOVECTRA, enhancing capabilities and achieving nearly all top-20 biopharma players' enterprise services touchpoints through competitive displacements, including an $9 million TSA contract for its Raman Insight BRT system in Q1. Management emphasized that while ongoing tariff policy changes and selective softness pose risks, their pricing power, supply-chain localization strategies, and Ignite-driven efficiencies will help maintain the growth track forward.